- Home
- TRV vs ARGX Comparison
TRV vs ARGX Comparison
Compare TRV & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRV
- ARGX
- Stock Information
- Founded
- TRV 1853
- ARGX 2008
- Country
- TRV United States
- ARGX Netherlands
- Employees
- TRV N/A
- ARGX N/A
- Industry
- TRV Property-Casualty Insurers
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRV Finance
- ARGX Health Care
- Exchange
- TRV Nasdaq
- ARGX Nasdaq
- Market Cap
- TRV 60.8B
- ARGX 51.1B
- IPO Year
- TRV 1996
- ARGX 2017
- Fundamental
- Price
- TRV $290.53
- ARGX $906.43
- Analyst Decision
- TRV Hold
- ARGX Strong Buy
- Analyst Count
- TRV 14
- ARGX 17
- Target Price
- TRV $290.00
- ARGX $910.63
- AVG Volume (30 Days)
- TRV 1.4M
- ARGX 374.7K
- Earning Date
- TRV 10-16-2025
- ARGX 10-30-2025
- Dividend Yield
- TRV 1.51%
- ARGX N/A
- EPS Growth
- TRV 30.54
- ARGX N/A
- EPS
- TRV 25.44
- ARGX 23.27
- Revenue
- TRV $48,404,000,000.00
- ARGX $3,683,281,000.00
- Revenue This Year
- TRV N/A
- ARGX $85.93
- Revenue Next Year
- TRV $2.60
- ARGX $35.17
- P/E Ratio
- TRV $11.43
- ARGX $36.13
- Revenue Growth
- TRV 6.75
- ARGX 92.98
- 52 Week Low
- TRV $230.23
- ARGX $510.06
- 52 Week High
- TRV $292.50
- ARGX $934.13
- Technical
- Relative Strength Index (RSI)
- TRV 67.54
- ARGX 67.61
- Support Level
- TRV $283.46
- ARGX $908.16
- Resistance Level
- TRV $290.62
- ARGX $932.29
- Average True Range (ATR)
- TRV 4.65
- ARGX 20.84
- MACD
- TRV 0.93
- ARGX 1.23
- Stochastic Oscillator
- TRV 85.76
- ARGX 76.93
About TRV The Travelers Companies Inc.
Travelers offers a broad product range and participates in both commercial and personal insurance lines. Its commercial operations offer a variety of coverage types for companies of any size but concentrate on serving midsize businesses. Its personal lines are roughly evenly split between auto and homeowners insurance.
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.